GlassScriptPhysician profile
Andrea Chavez
NPI 1679256960
$3,708.25
in general payments reported to CMS, 2019-2025
19 companies · $1,192 in 2025
The $1,192 reported for 2025 was more than what 89% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $2,516 · 2025: $1,192.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,705 · Travel and Lodging: $1,003.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,705.02 |
| Travel and Lodging | $1,003.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $1,488.38 | 2024 | Watchman Flx |
| Pfizer INC. | $513.07 | 2024-2025 | |
| E.R. Squibb & Sons, L.L.C. | $355.43 | 2024-2025 | Camzyos, Eliquis |
| Amgen INC. | $257.35 | 2024-2025 | Repatha, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $248.05 | 2024-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $158.75 | 2024-2025 | Verquvo, Winrevair |
| Actelion Pharmaceuticals US, INC. | $148.10 | 2024-2025 | Uptravi, Opsumit |
| Novartis Pharmaceuticals Corporation | $122.39 | 2024-2025 | |
| Lexicon Pharmaceuticals, INC. | $89.29 | 2024 | |
| Kiniksa Pharmaceuticals International, Plc | $88.41 | 2024 | Arcalyst |
| United Therapeutics Corporation | $57.18 | 2025 | Tyvaso |
| Daiichi Sankyo INC. | $33.53 | 2024-2025 | Injectafer |
| Janssen Pharmaceuticals, INC | $28.77 | 2024 | Xarelto |
| Novo Nordisk INC | $23.38 | 2025 | Wegovy |
| Bridgebio Pharma, INC. | $23.06 | 2025 | Attruby |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alnylam Pharmaceuticals INC. | $22.76 | 2025 | Amvuttra |
| Abiomed | $19.96 | 2024 | Impella |
| Scpharmaceuticals INC. | $16.37 | 2025 | |
| Analog Devices INC. | $14.02 | 2024 | Sensinel Cpm Wearable |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrea Chavez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.